Health Condition 1: C69-C72- Malignant neoplasms of eye, brain and other parts of central nervous system
Conditions
Interventions
None listed
Sponsors
Exsegen Genomics Research Pvt Ltd
Exsegen Genomics Research Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: (1) Subjects with suspected brain tumour on neuroimaging have not undergone any treatment for the suspected disease at the time of blood sample collection for this disease (2) Age- any age with proper consent/assent (3) Female patient - not pregnant (4) Provision of signed and dated informed consent form (5) Stated willingness to comply with all study procedures
Exclusion criteria
Exclusion criteria: (1) Patients who fail to meet all of the above criteria for cases will be excluded. Failing to meet any single criteria would be sufficient grounds for exclusion. (2) Prolonged cortico-steroid therapy, ideally steroid naïve (3) Active or latent hepatitis B or active hepatitis C or any uncontrolled infection (4) Human Immunodeficiency Virus (HIV) positive (5) Active infections, COViD19, HIV, HPV, HBV, HCV, Tuberculosis etc. (6) Patient has an investigational medicinal product within the last 30 days of blood collection. (7) PET -CT scan in past 14 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary objective: The primary objective of this study is to diagnose brain lesions with a specificity and sensitivity approaching a traditional biopsy in any patient having a radiological lesion that may represent a brain tumour. Timepoint: At 3 months, 6 months and 1 year from commencement of study | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objective: 1. To accurately predict already defined molecular subtypes of lesions based on serum exosomal profiles. 2. To assess the feasibility of being able to use this information to tailor therapy that can be studied in future. Timepoint: At one year after the start of the study | — |
Countries
India
Contacts
Public ContactDr Amitava Ray MBBS MD FRCSEd FRCS Neurosurgery
Founder Director and Clinical Lead
Outcome results
None listed